Abbott Laboratories $ABT Position Increased by Harbor Investment Advisory LLC

Harbor Investment Advisory LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 0.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,859 shares of the healthcare product maker’s stock after purchasing an additional 98 shares during the period. Harbor Investment Advisory LLC’s holdings in Abbott Laboratories were worth $3,517,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Kera Capital Partners Inc. lifted its holdings in shares of Abbott Laboratories by 11.3% in the 2nd quarter. Kera Capital Partners Inc. now owns 2,583 shares of the healthcare product maker’s stock worth $351,000 after purchasing an additional 262 shares during the last quarter. AG2R LA Mondiale Gestion D Actifs bought a new stake in shares of Abbott Laboratories in the 1st quarter worth approximately $8,562,000. Howe & Rusling Inc. lifted its holdings in shares of Abbott Laboratories by 6.4% in the 1st quarter. Howe & Rusling Inc. now owns 5,478 shares of the healthcare product maker’s stock worth $727,000 after purchasing an additional 329 shares during the last quarter. Maple Capital Management Inc. lifted its holdings in shares of Abbott Laboratories by 0.3% in the 1st quarter. Maple Capital Management Inc. now owns 169,957 shares of the healthcare product maker’s stock worth $22,545,000 after purchasing an additional 584 shares during the last quarter. Finally, eCIO Inc. bought a new stake in shares of Abbott Laboratories in the 1st quarter worth approximately $155,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 1.0%

Shares of ABT stock opened at $133.92 on Friday. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The stock has a market cap of $233.08 billion, a PE ratio of 16.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. The business’s fifty day moving average is $130.41 and its 200-day moving average is $131.32. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same period last year, the firm earned $1.14 EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ABT has been the topic of several recent analyst reports. Evercore ISI lifted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Mizuho lifted their target price on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, July 16th. Raymond James Financial cut their target price on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. Royal Bank Of Canada lifted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research note on Tuesday, July 15th. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $144.47.

Insider Activity

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.46% of the stock is owned by insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.